NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ:
XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX),
and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
MannKind Corp. Analyst Notes
On April 1, 2014, MannKind Corp.
(MannKind) announced that the U.S. Food and Drug Administration
(FDA) voted 13 to 1 in recommendation of AFREZZA's market approval.
The Company stated that if approved, AFREZZA would be the first
ultra rapid-acting mealtime insulin therapy available in the US.
"We are pleased with the Advisory Committee's approval
recommendation in support of AFREZZA, and we appreciate the
thoroughness of their review," said Alfred
Mann, Chairman and CEO of MannKind Corporation. "We look
forward to working with the FDA as they complete their evaluation
of AFREZZA." MannKind informed that the FDA will consider its
guidance in reviewing the New Drug Application (NDA) that was
submitted for AFREZZA, and Prescription Drug User Fee Act (PDUFA)
date for the FDA to complete its review of AFREZZA is April 15, 2014. The full analyst notes on
MannKind Corp. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/MNKD/report.pdf
--
Acceleron Pharma, Inc. Analyst Notes
On March 24, 2014, Acceleron
Pharma, Inc. (Acceleron) and Celgene Corp. (Celgene) announced the
successful publication of two papers online and in the April issue
of the Nature Medicine journal. The Company stated that the papers
explain how sotatercept and ACE-536 promote red blood cell
formation through an erythropoietin (EPO) independent mechanism in
mice. According to Acceleron, the studies suggest that sotatercept
and ACE-536 may promote and regulate the maturation of late-stage
red blood cell precursors and this distinct activity supports the
rationale for sotatercept and ACE-536 as potential novel therapies
to correct anemia, including the EPO-resistant anemia, in diseases
such as beta-thalassemia and myelodysplastic syndromes. The Company
added that the two papers will be available on the Publications
page of its website. The full analyst notes on Acceleron Pharma,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/XLRN/report.pdf
--
Steris Corp. Analyst Notes
On April 1, 2014, STERIS Corp.
(STERIS) announced that it has entered into a definitive agreement
to acquire Integrated Medical Systems International, Inc. (IMS) for
$165 million. The Company stated that
IMS is a privately held business, and an endoscope repair, surgical
instrument management and sterile processing consulting company.
According to STERIS, IMS will be integrated into the
Company's Healthcare segment as part of the Company's Specialty
Services business upon the closing of the transaction. "A key
element of our growth strategy has been to expand our Specialty
Services business through a combination of organic growth and
acquisition," said Walt Rosebrough,
President and CEO of STERIS Corporation. "We are excited about this
opportunity to build upon what we do best - help our hospital
Customers improve processes, increase quality, and save money." The
Company informed that the transaction is anticipated to close in Q1
FY 2015. The full analyst notes on STERIS Corp. are available to
download free of charge at:
http://www.AnalystsReview.com/04112014/STE/report.pdf
--
Retrophin, Inc. Analyst Notes
On March 27, 2014, Retrophin, Inc.
(Retrophin) announced the completion of acquisition of Manchester
Pharmaceuticals LLC for $62.5
million. The Company said that the acquisition adds two FDA
approved products to Retrophin including Chenodal, for patients
suffering from gallstones whom surgery poses an unacceptable health
risk due to disease or advanced age and Vecamyl for the management
of moderately severe to severe essential hypertension and
uncomplicated cases of malignant hypertension. "The acquisition of
Manchester Pharmaceuticals is a transformative event for Retrophin,
as we are now a commercial company with two FDA-approved products
on the market," said Martin Shkreli,
Founder and CEO of Retrophin. "We also look forward to raising
awareness of CTX, a rare, underdiagnosed and severe disease that is
treated with chenodeoxycholic acid. Early diagnosis of CTX is
essential, as many patients have permanent neurological damage that
could be avoided if the disease is detected early. As such, we are
building a team of medical science liaisons who will help educate
physicians about CTX." The full analyst notes on Retrophin, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/04112014/RTRX/report.pdf
--
NxStage Medical, Inc. Analyst Notes
On March 31, 2014, NxStage Medical
Inc. (NxStage) announced that it has been the recipient of 2014
Workplace Hero Award by the Northeast Chapter of the American Red
Cross. The Company stated that this award recognizes its continuous
efforts to provide support for the disadvantaged and dedication to
preparing employees to volunteer in the event of local and national
disasters. "We are honored to receive the American Red Cross
Northeast Chapter's Workplace Hero Award," stated Jeffrey Burbank, CEO of NxStage. "Giving back is
in our DNA - it's crucial not only to those with kidney disease,
but also to those in need in our own backyard." The full analyst
notes on NxStage Medical, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04112014/NXTM/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review